Global /South Korea /Healthcare /Biotechnology /115180

Qurient Co., Ltd.

115180

• KRX: 115180 • Delayed

39,300KRW -0.6%

25.64 USD

As of 5 June 2026, Qurient Co., Ltd. has a market cap of $1.04B USD, ranking #10532 globally and #282 in South Korea. It ranks #947 in the Healthcare sector, and #177 in the Biotechnology industry.

Global Rank

10532

Country Rank

282

Sector Rank

947

Industry Rank

177

Key Stats

Market Cap

$1.04BUSD

1.59T KRW

Enterprise Value

$1.02BUSD

1.56T KRW

Revenue (TTM)

$4.56MUSD

6.98B KRW

EBITDA (TTM)

-$18.79MUSD

-28.8B KRW

Net Income (TTM)

-$19.61MUSD

-30.05B KRW

PS Ratio

227.5

PB Ratio

40.5

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Ki-Yean Nam open_in_new

Founded

2008

Website

qurient.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.6%	6%	-2.3%	14%	113%	31%	289%	373%	75%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	115180 (주)큐리언트 ISIN: KR7115180002 Shares Out.: Shares Outstanding: 37.483M¹ Shares Float: 29.537M² TV: TradingView: KRX: 115180 SA: Stock Analysis: KRX: 115180 YF: Yahoo Finance: 115180.KS GF: Google Finance: KRX: 115180 BA: Barron's: 115180 MS: Morningstar: XKRX: 115180	39,300 KRW	TV: TradingView: KRX: 115180 SA: Stock Analysis: KRX: 115180 YF: Yahoo Finance: 115180.KS GF: Google Finance: KRX: 115180 BA: Barron's: 115180 MS: Morningstar: XKRX: 115180

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Qurient Co., Ltd.

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 4K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$27.89B 42.76T KRW 3K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.27B 20.33T KRW 1K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.46B 8.37T KRW 427%	-	South Korea
Peptron, Inc. KRX: 087010	$3.96B 6.07T KRW 282%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.23B 3.42T KRW 116%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 18K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 15K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 5K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 4K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 3K%	-	United States

chevron_leftBack